Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eliglustat + ICI in Advanced Cancers
NCT04944888Phase 1Completed
- Sponsor
- Chinese PLA General Hospital
- Start
- Jul 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of eliglustat in solid tumor and hematologic malignancy (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Number of subjects occuring treatment related adverse events. Started Jul 2021; status: completed.
02
Drugs
eliglustat
03
Conditions
solid tumorhematologic malignancy
Beyond the preview
Go deeper on NCT04944888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04944888.